24 Results for "

HG2

" in MedChemExpress (MCE) Product Catalog:
Products (24)

24 Results for "HG2" in MCE Product Catalog:

Cat. No.: HY-D1549
CAS No.: 1181844-41-6
o-Pah is a BODIPY derivative with an -NH2 and -OH substituted meso-Ph group. o-Pah exhibits metal-induced J-aggregation in the presence of Cu 2+ and a specific fluorescence enhancement for Hg 2+ (Ex/Em=483/(495-600) nM) .
loading...
    loading...
Cat. No.: HY-143234
CAS No.: 2757155-96-5
Research Areas:  

Cancer

mIDH1-IN-1 (compound 43) is a potent and selective mIDH1 (mutant isocitrate dehydrogenases 1) inhibitor, with an IC50 of 961.5 nM. mIDH1-IN-1 potently inhibits intracellular 2-HG (2-hydroxyglutarate) production in HT1080 cells, with an EC50 of 208.6 ± 8.0 nM. mIDH1-IN-1 shows a significant anti-proliferation activity on IDH1 mutant-U-87 cells, with an IC50 of 41.8 nM. mIDH1-IN-1 is an antitumor agent, and can be used for IDH1 mutated solid tumors research .
loading...
    loading...
Cat. No.: HY-145743
CAS No.: 1111233-06-7
Research Areas:  

Cancer

CP-17 is a potent and selective IDH2/R140Q inhibitor with an IC50 of 40.75 nM. CP-17 exhibits excellent selectivity of >55-fold against the wild-type IDH2. CP-17 exhibits robust D-2-HG suppression activity in TF-1 (IDH2/R140Q) cells and reverses the cellular differentiation block induced by the R140Q mutation. CP-17 can be used for acute myeloid leukemia (AML) research .
loading...
    loading...
Cat. No.: HY-104042R
CAS No.: 1644545-52-7
Synonyms: AG-881 (Standard)
Vorasidenib (Standard) is the analytical standard of Vorasidenib (HY-104042). This product is intended for research and analytical applications. Vorasidenib (AG-881) is an orally available, brain penetrant second-generation dual mutant isocitrate dehydrogenases 1 and 2 (mIDH1/2) inhibitor. Vorasidenib (AG-881) exhibits nanomolar inhibition of (D)-2-hydroxyglutarate (D-2-HG), and the IC50 ranges of 0.04~22 nM against IDH1 R132C, IDH1 R132G, IDH1 R132H and IDH1 R132S and 7~14 nM against IDH2 R140Q and 130 nM against IDH2 R172K. Vorasidenib can be used for the study of grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1/2 mutation [2].
loading...
    loading...